...I study of lead candidate ONL1204 to treat retinal detachment and to start Phase Ib trials of the Fas inhibitor...

...New Enterprise Associates. Sagimet expects top-line data in mid-2020 from a Phase II trial of TVB-2640...

...13 and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640...
...Phase I testing to treat NASH, TVB-2640 reduced mean hepatic de novo lipogenesis from baseline. TVB-2640...
...3-V Biosciences Inc., Menlo Park, Calif. Ascletis Pharma Inc. (HKSE:1672), Hangzhou, China Business: Hepatic Hongjiang Li FAS inhibitor (TVB-2640) 3-V...

...round and granted lead investor Ascletis Pharma Inc. (HKEX:1672) exclusive rights in Greater China to TVB-2640...
...TVB-2640 is the first FASN inhibitor to enter clinical development, according to BioCentury's BCIQ database. Hongjiang Li FAS inhibitor...
...is the first FASN inhibitor to enter clinical development, according to BioCentury's BCIQ database. Hongjiang Li FAS inhibitor (TVB-2640) 3-V...

...pinometostat in Phase I testing to treat leukemia. 3-V Biosciences Inc. has the FASN inhibitor TVB-2640...

...that a once-daily 50 mg dose of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) candidate TVB-2640...
...Menlo Park, Calif. Product: TVB-2640 Business: Endocrine/Metabolic Molecular target: Fatty acid synthase (FASN; FAS) Description: FAS inhibitor...
...of the abdomen and change in skin sebum production Status: Phase I data Milestone: NA Allison Johnson TVB-2640 3-V...

...therapy targeting cancer/testis antigen 1B (NY-ESO-1; CTAG1B) to treat cancer Ph I/II 3-V Biosciences Inc. TVB-2640...

...also participated. 3-V expects early efficacy data in 2015 from a Phase I trial of TVB-2640...
...acid synthase ( FASN ; FAS) inhibitor to treat advanced solid tumors. The company said TVB-2640...

...as a-lipoic acid could help protect normal cells from the toxic effects of C75, a FAS inhibitor...